Big Biotechs Scare Off Short Sellers
The April 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The April 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
Gilead Science was supposed to be coming back as a company on the heels of its first major acquisition in years. Unfortunately, the post-earnings reaction has not been any help on that…
Gilead Sciences released disappointing first-quarter financial results late Tuesday and shares tumbled early Wednesday.
Gilead Sciences is set to report its most recent quarterly results after the markets close on Tuesday, the first since an announced collaboration with Sangamo Therapeutics.
The April 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The March 29 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks decreased.
The March 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The February 28 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
These five top companies with different health care businesses all can provide nice exposure to the sector in growth portfolios. All are rated Buy at Jefferies and make sense now.
The short interest data are out for the most recent settlement date, February 15. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, with big…
Cancer immunotherapy approaches have attracted the attention of Big Pharma in the past. New technology from Stanford University probably will be no exception if Phase 1 results are positive.
If the collaboration between Sangamo and Kite Pharma works out, some investors might just ask why Gilead did not just acquire Sangamo.
Sangamo Therapeutics saw its shares make a solid gain on Thursday after the company announced that it had entered into a worldwide partnership with a subsidiary of Gilead Sciences.
With indiscriminate selling absolutely punishing some of the top large cap biotech stocks, one analyst says now is the time to buy.
The January 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.